Complete response induced by fotemustine given as single agent in a patient with primary central nervous system non-Hodgkin aggressive lymphoma relapsed after high-dose chemotherapy and autologous stem cell support by Pennese, Elsa et al.
2188
Leukemia & Lymphoma, November 2011; 52(11): 2188–2189
© 2011 Informa UK, Ltd.
ISSN: 1042-8194 print / 1029-2403 online
DOI: 10.3109/10428194.2011.585672
  Correspondence: Dr. Elsa Pennese, Hematology and Stem Cell Transplantation Unit, P.O.  ‘ Vito Fazzi ’  , Piazza F. Muratore, 73100 Lecce, Italy. E-mail:  pennese.
ematolecce@libero.it   
 Received    17    February    2011  ;  revised    26    April    2011 ;    accepted    2    May    2011  
                     LETTER  TO  THE  EDITOR 
              Complete response induced by fotemustine given as single agent in a 
patient with primary central nervous system non-Hodgkin aggressive 
lymphoma relapsed after high-dose chemotherapy and autologous 
stem  cell  support      
    Elsa      Pennese  ,        Carolina     Vergine  ,        Rosella      Matera  ,        Michela      Dargenio  ,        Pasquale      Forese     &         Nicola  Di      Renzo    
 Hematology and Stem Cell Transplantation Unit,  ‘ Vito Fazzi ’  Hospital, Lecce, Italy                             
  Despite recent therapeutic advances, primary central ner-
vous system lymphoma (PCNSL) shows the worst prognosis 
among all non-Hodgkin lymphomas (NHLs), with a 5-year 
survival rate ranging from 4 to 40% [1,2]. Front-line therapy 
for patients with PCNSL is a combined chemo-radiotherapy 
regimen. High-dose chemotherapy with autologous stem 
cell support (ASCT) is still under investigation as consolida-
tion therapy [3]. Th   is therapeutic approach has improved the 
complete response rate and median survival, but the prog-
nosis of PCNSL remains poor with a high rate of fatal relapse. 
Th   ere is no standardized approach for refractory or relapsed 
PCNSL, with reported 1-year progression-free survival (PFS) 
ranging from 13 to 53% and 1-year overall survival (OS) of 
about 50% [4  –  7]. 
 Fotemustine (FTM) is a third-generation nitro-sourea with 
elevated lipophilic properties, which contributes to facilitate 
its passage through the blood  –  brain barrier and into malig-
nant cells. Th   e drug has been approved in the treatment of 
malignant metastatic melanoma and primary brain tumors 
[8]. Recently the drug has been used instead of carmustine in 
a novel fotemustine-based high-dose conditioning regimen 
(FEAM) in patients with lymphoma [9]. After a follow-up of 
17 months, none of the patients with documented central 
nervous system involvement before ASCT showed disease 
progression at the level of the central nervous system, which 
is consistent with the active passage of FTM through the 
blood–brain barrier. 
 We report here the case of a patient with relapsing PCNSL 
after front-line and consolidation therapy, who received 
fotemustine monotherapy as salvage therapy. 
  A 33-year-old male patient was admitted because of 
signs of intracranial hypertension. Cerebral computed 
tomography (CT) scan and magnetic resonance (MR) 
revealed a tumor localized in the median deep region of 
the brain. Immunohistochemical analysis of the tissue (ste-
reotactic biopsy) diagnosed diff  use large B-cell lymphoma. 
Th   e staging work-up was negative for other sites of disease 
and the defi  nitive diagnosis was PCNSL. Front-line therapy 
  consisted of two courses of high-dose methotrexate (8 mg/
m2), discontinued because of persistent mucositis (World 
Health Organization [WHO] grade 4), followed by three 
courses of L-VAMP (vincristine 1.5 mg/m2 IV on day 1, 
methotrexate 1000 mg/m2 IV on day 1, cytosine arabinoside 
100 mg/m2 IV on day 1, dexamethasone 10 mg/m2 IV on 
days 1–5) combined with intrathecal (IT) lyposomal cytara-
bine and whole-brain radiation therapy at the total dose of 
40 Gy. At the end of the front-line treatment program, com-
plete response (CR) was documented by a negative cerebral 
CT scan and MR. After 3 months the patient received the 
FEAM regimen (fotemustine 150 mg/m  2   on days 8 and 
7; etoposide 200 mg/m  2   on days 6, 5, 4, and 3; 
cytarabine 400 mg/m  2   on days 6, 5, 4, and 3; mel-
phalan 140 mg/m  2   on day 2) with autologous stem cell 
support as consolidation treatment. 
  After a follow-up of 21 months, progressive hearing 
loss and ataxia appeared; CT scan and MR [Figure 1(a)] 
showed a cerebellar relapse. FTM was administered every 
15 days at the dose of 100 mg/m  2   as salvage therapy. The 
patient achieved a second complete response after eight 
courses of FTM, as documented by MR [Figure 1(b)]. 
  FTM was well tolerated, with the main hematological 
toxicity consisting of grade II thrombocytopenia. No extra-
hematological toxicities were recorded. After a follow-up of 
17 months the patient is still in CR, as confi  rmed by CT and 
positron emission tomography (PET) scans. 
  To our knowledge this represents the first report of CR 
achieved with fotemustine as a single agent in a patient 
with PCNSL relapsing after high-dose therapy and stem 
cell support. It is noteworthy that complete response in 
this patient has been achieved despite previous exposure 
to fotemustine, suggesting that the drug does not induce 
resistance. 
  PCNSLs are rare, aggressive malignancies with a poor 
outcome, but potentially curable tumors. The poor prog-
nosis of patients with PCNSL is mainly due to the low inci-
dence of the disease, which does not permit a   consistent Letter to the Editor       2189
number of patients to be enrolled in randomized clini-
cal trials. In addition, the advanced age of patients at 
diagnosis, comorbidities, and poor performance status 
make the diagnosis as well as optimal treatment difficult. 
  The prognosis of relapsed  –  refractory patients with 
PCNSL is poor with the available drugs, and new agents 
are awaited in this field. An alkylating agent such as fote-
mustine could be an interesting candidate, since this 
drug is able to cross the blood  –  brain barrier. FTM is a 
third-generation chloroethylnitrosourea containing a 
phosphoalanine carrier group attached to the nitrosourea 
radical. The phosphoalanine group makes the drug highly 
lipophilic, as shown by the octanol/water partition coef-
fcient, which is in the optimal range compared with other 
nitrosoureas such as BCNU [1,3-bis(2-chloroethyl)-1-
nitrosourea] and CCNU [1-(2-chloroethyl)-3-cyclohexyl-
1-nitrosourea] [8]. However, more patients have to be 
treated and a formal trial should be conducted to define 
the exact role of fotemustine in the treatment of relapsing 
PCNSL. 
  Potential conﬂ  ict of interest:   Disclosure forms provided 
by the authors are available with the full text of this article at 
www.informahealthcare.com/lal .    
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Figure 1.         Magnetic resonance showed (a) cerebellar relapse after consolidation therapy and (b) complete response after fotemustine salvage 
therapy.  